Mengyun Ke

Mengyun Ke

Auto-generated profile, based on publicly available information

Mengyun Ke

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HWHui Wang
Hui Wang
MKMengyun Ke
Mengyun Ke
YTYuwei Tian
Yuwei Tian
JWJing Wang
Jing Wang
BLBing Li
Bing Li
CZChanglin Zhou
Changlin Zhou

1 February 2011 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
JDJie Dou
Jie Dou
LCLili Chen
Lili Chen
GXGe Xu
Ge Xu
LZLei Zhang
Lei Zhang
HZHuimin Zhou
Huimin Zhou
CZChanglin Zhou
Changlin Zhou

7 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MKMengyun Ke
Mengyun Ke
TXTao Xu
Tao Xu
NLNa Li
Na Li
YRYifan Ren
Yifan Ren
ASAihua Shi
Aihua Shi
HHHaiqi He
Haiqi He
Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria

31 December 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
JZJia Zhang
Jia Zhang
MKMengyun Ke
Mengyun Ke
YRYifan Ren
Yifan Ren
JBJianbin Bi
Jianbin Bi
ZDZhaoqing Du
Zhaoqing Du
RWRongqian Wu
Rongqian Wu
Background. Hepatectomy remains one of the most effective treatments for patients with hepatocellular carcinoma (HCC); however, it can lead to serious complications. Irisin, a key regulator of energy metabolism, is secreted into the circulation by shedding of the extracellular portion of the fibronectin type III domain-containing 5 (FNDC5). We have shown that irisin administration alleviates liver ischemia-reperfusion injury in mice. However, the role of preoperative irisin levels in HCC patients who underwent hepatectomy remained unknown. The purpose of this study was to determine how irisin expression changes in HCC and to explore the relationship between preoperative serum irisin levels and complications after hepatectomy. Methods. FNDC5/irisin expression data in HCC were extracted from The Cancer Genome Atlas (TCGA) dataset. A total of 219 participants, including 102 healthy controls and 117 HCC patients, were recruited in this study. All HCC patients underwent hepatectomy at the First Affiliated Hospital of the Xi’an Jiaotong University. Preoperative serum irisin levels were measured by ELISA. Postoperative complications were assessed using the comprehensive complication index (CCI) score. The Pearson rank correlation coefficient was computed to assess the correlation between preoperative serum irisin levels and postoperative CCI scores. Results. In TCGA dataset, FNDC5/irisin expression was downregulated in HCC tissues (P<0.001). Similarly, serum irisin levels were decreased in HCC patients (P<0.001). Low preoperative serum irisin levels were significantly correlated with high CCI scores after hepatectomy. Conclusions. Irisin may be a novel serum biomarker in the diagnosis of HCC and a predictor of complications after hepatectomy.

1 July 2016 in Oncotarget
Verified
Journal Article
Open access
MKMengyun Ke
Mengyun Ke
HWHui Wang
Hui Wang
YZYiran Zhou
Yiran Zhou
JLJingwen Li
Jingwen Li
YLYang Liu
Yang Liu
CZChanglin Zhou
Changlin Zhou
SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice

29 September 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MKMengyun Ke
Mengyun Ke
JKJong-Won Kim
Jong-Won Kim
MXMeishu Xu
Meishu Xu
JWJingyuan Wang
Jingyuan Wang
LLLingyi Liu
Lingyi Liu
WXWen Xie
Wen Xie
Protein S -sulfinylation is a reversible oxidative cysteine modification, but its contribution to acute liver injury such as those induced by acetaminophen (APAP) overdose has not been reported. Sulfiredoxin-1 (SRXN1) is the only oxidoreductase known to reduce the sulfinylated proteins, yet the substrates and mechanisms through which it protects against acute liver injury are unclear. Here, we show that hepatic protein S -sulfinylation was markedly upregulated in APAP-overdose patients and mice. Hepatocyte-specific knockout or pharmacological inhibition of Srxn1 sensitized mice to APAP-induced acute liver injury. In contrast, overexpression of SRXN1, but not its oxidoreductase-dead C99S mutant, protected mice from APAP-induced liver injury. Mechanistically, we identified the deubiquitinase ubiquitin-specific protease 7 (USP7) as an SRXN1 substrate required for hepatoprotection. USP7 inhibition worsened APAP-induced liver injury, whereas its overexpression alleviated injury by stabilizing its deubiquitinase substrate heme oxygenase-1 (HO-1). Loss of SRXN1 enhanced S -sulfinylation of USP7 at Cys315, promoting its ubiquitination and degradation. SRXN1 expression correlated with USP7 levels in human liver samples. Delayed lipid nanoparticle (LNP) delivery of SRXN1 messenger RNA (mRNA) mitigated established APAP-induced liver injury beyond the therapeutic window of N -acetylcysteine. These findings define an SRXN1-USP7-HO-1 axis as a promising therapeutic target for oxidative liver injury and highlight LNP-mediated SRXN1 mRNA delivery as a potential treatment approach.